Technical Analysis for GBT - Global Blood Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
48.87 | 2.00% | 0.96 |
GBT closed up 2.0 percent on Friday, January 18, 2019, on 46 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical GBT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Narrow Range Bar | Range Contraction | 0.00% |
| Jan 18 | NR7 | Range Contraction | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 18 | Overbought Stochastic | Strength | 0.00% |
| Jan 17 | 180 Bullish Setup | Bullish Swing Setup | 2.00% |
| Jan 17 | Outside Day | Range Expansion | 2.00% |
| Jan 17 | Wide Bands | Range Expansion | 2.00% |
| Jan 17 | Overbought Stochastic | Strength | 2.00% |
| Jan 16 | Shooting Star Candlestick | Bearish | 4.53% |
| Jan 16 | Stochastic Sell Signal | Bearish | 4.53% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-01
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in double-blind Phase I/II clinical trial indicated for the treatment of sickle cell disease. The company also focuses on developing an oral prophylactic therapy for hypoxemic pulmonary disorders and hereditary angioedema. The company was founded in 2011 and is based in South San Francisco, California.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more GBT news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 68.05 |
| 52 Week Low | 30.15 |
| Average Volume | 1,279,729 |
| 200-Day Moving Average | 42.5464 |
| 50-Day Moving Average | 40.1945 |
| 20-Day Moving Average | 42.442 |
| 10-Day Moving Average | 45.34 |
| Average True Range | 2.388 |
| ADX | 24.19 |
| +DI | 29.6678 |
| -DI | 11.9081 |
| Chandelier Exit (Long, 3 ATRs ) | 41.766 |
| Chandelier Exit (Short, 3 ATRs ) | 42.084 |
| Upper Bollinger Band | 49.4127 |
| Lower Bollinger Band | 35.4713 |
| Percent B (%b) | 0.96 |
| BandWidth | 32.848122 |
| MACD Line | 2.1513 |
| MACD Signal Line | 1.5342 |
| MACD Histogram | 0.6171 |
| Fundamentals | Value |
|---|---|
| Market Cap | 2.13 Billion |
| Num Shares | 43.7 Million |
| EPS | -2.46 |
| Price-to-Earnings (P/E) Ratio | -19.87 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 5.19 |
| PEG Ratio | -0.38 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 50.64 | ||||
| Resistance 3 (R3) | 50.46 | 49.70 | 50.35 | ||
| Resistance 2 (R2) | 49.70 | 49.25 | 49.79 | 50.25 | |
| Resistance 1 (R1) | 49.28 | 48.97 | 49.49 | 49.46 | 50.15 |
| Pivot Point | 48.52 | 48.52 | 48.62 | 48.61 | 48.52 |
| Support 1 (S1) | 48.10 | 48.07 | 48.31 | 48.28 | 47.59 |
| Support 2 (S2) | 47.34 | 47.79 | 47.43 | 47.49 | |
| Support 3 (S3) | 46.92 | 47.34 | 47.40 | ||
| Support 4 (S4) | 47.10 |
